CTKBHealthcare · Medical DevicesThe 4 Wall Street analysts covering Cytek Biosciences, Inc. hold a median 12-month price target of $5 — +8.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 12 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Cytek Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (36): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CTKB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +8.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 May 2026 | Stephens & Co. | Maintains | Overweight | $5.50 → $4.75 |
| 12 May 2026 | Morgan Stanley | Maintains | Equal-Weight | $6.00 → $5.50 |
| 8 Jan 2026 | TD Cowen | Maintains | Buy | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Overweight | — |
| 28 May 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 12 May 2025 | Goldman Sachs | Maintains | Sell | — |
| 19 Mar 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 4 Mar 2025 | Piper Sandler | Maintains | Overweight | — |
| 11 Nov 2024 | Piper Sandler | Maintains | Overweight | — |
| 13 Aug 2024 | Piper Sandler | Maintains | Overweight | — |
| 13 May 2024 | Piper Sandler | Maintains | Overweight | — |
| 6 Mar 2024 | Piper Sandler | Maintains | Overweight | — |
| 29 Feb 2024 | Goldman Sachs | Maintains | Buy | — |
| 14 Dec 2023 | Stephens & Co. | Initiates | Overweight | — |
| 9 Nov 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 24 Oct 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 16 Oct 2023 | Piper Sandler | Maintains | Overweight | — |
| 19 July 2023 | Raymond James | Initiates | Market Perform | — |
| 11 May 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 10 May 2023 | Goldman Sachs | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTKB appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Cytek Biosciences, Inc. returned +11.6% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 2% of US stocks
Cheaper than 42% of US stocks
Cheaper than 48% of US stocks
Cheaper than 84% of US stocks
Higher than 40% of US stocks
Higher than 42% of US stocks
Higher than 72% of US stocks
Higher than 20% of US stocks
Higher than 12% of US stocks
Higher than 30% of US stocks
Higher than 30% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cytek Biosciences, Inc. has a market value of $599.2M and an enterprise value of $363.7M.
Revenue in the twelve months to 30 June 2026: $206.7M. The latest quarter grew 5.6% year on year.
Net income over the same four quarters: −$80.6M, a −39.0% net margin.
Diluted earnings per share, trailing twelve months: $−0.62.
Free cash flow in the twelve months to 30 June 2026: −$12.2M.
Cytek Biosciences, Inc. spent $63K on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 374.5×; forward P/E: 65.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Cytek Biosciences, Inc. employs 682 people — $303K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Cytek Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Sysmex Europe and Cytek Biosciences announced a collaboration to expand access to advanced clinical flow cytometry. The announcement was made from Fremont, California, and Hamburg, Germany.
Why it matters — The partnership could broaden the reach of Cytek's flow cytometry technology in clinical markets through Sysmex Europe's distribution network.
Cytek Biosciences will showcase its spectral flow cytometry solutions at the ESCCA 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course, this fall. The company is highlighting the expanding role of spectral flow cytometry in clinical research as laboratories seek deeper cellular insights and streamlined cell analysis.
Why it matters — A CTKB watcher would care because the company's participation in these leading clinical cytometry events signals its focus on growing its presence and visibility in the clinical research market for spectral flow cytometry.
Cytek Biosciences, Inc. (Nasdaq: CTKB), a cell analysis solutions company, announced it will participate in upcoming investor conferences. The announcement, dated September 1, 2026, was made via GlobeNewsWire.
Why it matters — Participation in investor conferences gives CTKB watchers upcoming opportunities to hear company updates and insights directly from management.
A jury found in Cytek's favor on three of four asserted patent claims brought by Beckman Coulter, finding noninfringement and invalidity on those claims, but found infringement under the doctrine of equivalents on one claim and awarded $56 million in damages. Cytek plans to challenge the remaining finding through post-verdict motions.
Why it matters — The mixed verdict and $56 million damages award create uncertainty around a significant legal liability, while Cytek's plan to challenge the finding leaves the outcome unresolved.
Seeking Alpha published the transcript of Cytek Biosciences, Inc.'s (CTKB) Q2 2026 earnings call. The item indicates the company held its quarterly earnings call and its transcript is now available.
Why it matters — A Cytek watcher would care because the earnings call transcript provides direct insight into the company's recent quarterly performance and management commentary.
The 4 Wall Street analysts covering Cytek Biosciences, Inc. have a median 12-month price target of $5, with estimates ranging from $4.75 to $7.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Cytek Biosciences, Inc., 2 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cytek Biosciences, Inc. 64 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Cytek Biosciences, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +8.5% from the last close, and Ticker Nerd's factor model ranks Cytek Biosciences, Inc. 64 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Cytek Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTKB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.75 to $7.5 over the next 12 months.
Cytek Biosciences, Inc. returned +11.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Cytek Biosciences, Inc. is a cell analysis solutions company that develops and markets advanced flow cytometry systems, reagents, software, and services for biomedical research and clinical applications.
The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry". Sysmex Europe and Cytek Biosciences announced a collaboration to expand access to advanced clinical flow cytometry. The announcement was made from Fremont, California, and Hamburg, Germany.
Cytek Biosciences, Inc. is a cell analysis solutions company that develops and markets advanced flow cytometry systems, reagents, software, and services for biomedical research and clinical applications. The company’s portfolio centers on its Full Spectrum Profiling technology, which supports high-resolution, high-content, and high-sensitivity analysis of single cells. Its current product lineup includes the Aurora and Northern Lights cell analyzers, the Aurora CS cell sorter, and related integrated tools designed to help researchers study complex biological samples. Cytek Biosciences also offers conventional flow and image-based flow cytometry products through its acquired Amnis and Guava businesses, expanding its reach across cell analysis workflows. The company serves life science researchers and clinical laboratories with solutions used in areas such as immunology, cancer research, infectious disease, and inflammatory disease studies. Headquartered in Fremont, California, Cytek Biosciences focuses on providing a comprehensive platform for cell analysis in global research and applied science markets.
CEO Dr. Wenbin Jiang Ph.D. · 682 employees · United States · https://cytekbio.com
